½ÃÀ庸°í¼­
»óǰÄÚµå
1609150

¼¼°èÀÇ ¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ½ÃÀå : ¼­ºñ½º, Áúȯ, Áø´Ü ¹æ¹ý, ÃÖÁ¾ ¿ëµµº° ¿¹Ãø(2025-2030³â)

Neglected Tropical Diseases Diagnosis Market by Service (Centralized Service, POC Service), Disease (African Trypanosomiasis, Buruli Ulcer, Chagas Disease), Diagnostic Method, End-Use - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 198 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ½ÃÀåÀº 2023³â 66¾ï 9,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 70¾ï 4,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµÇ¸ç CAGR 5.80%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 99¾ï 3,000¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼Ò¿Ü¿­´ëÁúȯ(Neglected Tropical Diseases : NTDs)Àº ÁÖ·Î ¿­´ë ¹× ¾Æ¿­´ë Áö¿ª¿¡¼­ 10¾ï ¸í ÀÌ»óÀÇ »ç¶÷µéÀ» ¾Î°íÀÖ´Â ´Ù¾çÇÑ °¨¿°À» Æ÷ÇÔÇÕ´Ï´Ù. NTDÀÇ Á¤È®ÇÑ Áø´ÜÀÇ Çʿ伺Àº ÀÌ·¯ÇÑ Áúº´ÀÌ ¸¸¼º °Ç°­ ¹®Á¦, ¼è¾àÇϰÔÇÏ´Â °¨¿°, »çȸÀû ½ºÆ¼±×¸¶ ¿øÀÎÀÌ µÇ´Â °ÍÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ±× ¿ëµµ´Â ±âº»ÀûÀÎ Áø´Ü Åø·ÎºÎÅÍ Ã·´ÜÀûÀÎ ºÐÀÚ ÇØ¼® ¼ö¹ý±îÁö ´Ù¾çÇϸç, Áúº´ °¨½Ã, È¿°úÀûÀÎ Ä¡·á °èȹ, Àü¿° °¨¼Ò¿¡ ÇʼöÀûÀÔ´Ï´Ù. º´¿ø, Áø´Ü ½ÇÇè½Ç, ¿¬±¸ ±â°ü µîÀÌ ÀÖÀ¸¸ç, ÀÌµé ±â°üÀº ÀÌ·¯ÇÑ Áø´ÜÀ» ÀÌ¿ëÇÏ¿© Áý´Ü ¹ß»ýÀ» °ü¸®Çϰí ÀÇ·á °ü¸®Ã¥À» À̲ø°í ¿ªÇÐ Á¶»ç¸¦ ½Ç½ÃÇÕ´Ï´Ù. È¿°úÀûÀÎ ÇØ°áÃ¥À» Áß½ÃÇÏ´Â °ü¹Î ÆÄÆ®³Ê½Ê°ú ¼¼°è º¸°Ç ÀÌ´Ï¼ÅÆ¼ºê Áõ°¡°¡ ½ÃÀå È®´ëÀÇ ±âȸ¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. ±×¸®°í ºñÁ¤ºÎ ±â°üÀÇ ÅõÀÚ Áõ°¡, ºÐÀÚ °Ë»ç³ª Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î °Ë»ç¿Í °°Àº Áø´Ü ±â¼úÀÇ Çõ½Å, NTDs¸¦ ¾Î°í ÀÖ´Â Áö¿ª¿¡¼­ÀÇ ÇコÄɾÀÇ ¾×¼¼½º È®´ë µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. À¯Çà Áö¿ª¿¡¼­ ºÎÁ·ÇÑ °Ç°­ °ü¸® ÀÎÇÁ¶ó, Á¦ÇÑµÈ ÀνÄ, ±ÔÁ¦ À庮, °í±Þ Áø´Ü µµ±¸ÀÇ ³ôÀº ºñ¿ë µîÀ» Æ÷ÇÔÇÕ´Ï´Ù. NTD¸¦ À§ÇÑ Àúºñ¿ëÀ¸·Î ½Å¼ÓÇÑ Áø´Ü °Ë»ç, ƯÈ÷ ÀúÀÚ¿ø ȯ°æ¿¡¼­µµ ½Ç½Ã °¡´ÉÇÑ Áø´Ü °Ë»ç¸¦ °³¹ßÇÒ ¼ö ÀÖ´Â ±âȸ°¡ ÀÖ½À´Ï´Ù. Çõ½ÅÀº ºü¸£°í Á¤È®ÇÑ °á°ú¸¦ Á¦°øÇÏ´Â ÈÞ´ë¿ë ¹× ÅëÇÕ Áø´Ü Ç÷§Æû¿¡ ÁýÁßÇÒ ¼ö ÀÖÀ¸¸ç, µ¥ÀÌÅÍÀÇ º¸±Þ°ú °ü¸®¸¦ À§ÇÑ µðÁöÅÐ °Ç°­ ±â¼ú¿¡ ÀÇÇØ °­È­µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇϱâ À§ÇØ ±â¾÷Àº Á¤ºÎ¿Í NGO¿ÍÀÇ Àü·«Àû Á¦ÈÞ¿¡ ÁÖ·ÂÇÏ°í ½Å±Ô Áø´Ü ¾à¹°ÀÇ ¿¬±¸ °³¹ß¿¡ ÅõÀÚÇϰí È®Àå °¡´ÉÇÑ »ý»ê ±â¼ú¿¡ Á¾»çÇØ¾ßÇÕ´Ï´Ù. ÀÌ ½ÃÀå¿¡¼­ Áö¼ÓÀûÀ¸·Î ¼ºÀåÇϱâ À§Çؼ­´Â ¾ö°ÝÇÑ ±ÔÁ¦ ȯ°æÀ» ±Øº¹ÇÏ°í °Ç°­ °ü¸® Á¦°ø À庮À» ÇØ°áÇϱâ À§ÇØ ½Ç»ç¸¦ ¼öÇàÇØ¾ßÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 66¾ï 9,000¸¸ ´Þ·¯
ÃßÁ¤³â(2024) 70¾ï 4,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 99¾ï 3,000¸¸ ´Þ·¯
CAGR(%) 5.80%

½ÃÀå ¿ªÇÐ: ±Þ¼ÓÈ÷ ÁøÈ­ÇÏ´Â ¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ðÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ȹµæÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ» »Ó¸¸ ¾Æ´Ï¶ó, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¶Ç´Â ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¼Ò¿Ü¿­´ëÁúȯ¿¡ ÀÓÇÏ´Â ÇÁ·Î±×·¥ Áõ°¡
    • ¿­´ë¡¤¾Æ¿­´ë ±¹°¡¿¡¼­ ¼Ò¿Ü¿­´ëÁúȯÀÇ À¯º´·ü »ó½Â
    • Áúº´ÀÇ Á¶±â ¹ß°ß¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Àú°³¹ß±¹¿¡¼­ ¼Ò¿Ü¿­´ëÁúȯ¿¡ ´ëÇÑ Ä¡·áÀǽÄÀÇ ºÎÁ·
  • ½ÃÀå ±âȸ
    • °íµµÀÇ ¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ±â±âÀÇ °³¹ßÀÇ °íÁ¶
    • Çõ½ÅÀûÀÎ ¼Ò¿Ü¿­´ëÁúȯ Áø´Ü¹ýÀ» °³¹ßÇϱâ À§ÇÑ ¿¬±¸ °³¹ßÀÇ È°¼ºÈ­
  • ½ÃÀåÀÇ °úÁ¦
    • Áø´ÜÀ» À§ÇÑ Ç¥ÁØÈ­ ÅøÀÇ ºÎÁ·

Porter's Five Force : ¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Force Framework´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Force Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂûÀ» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ãȯ°æ ¿äÀÎÀº ¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇϴµ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾ÕÀ» ³»´Ùº» Àû±ØÀûÀÎ ÀÇ»ç°áÁ¤À» ÇÒ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ½ÃÀå¿¡¼­ °æÀï ±¸µµ ÆÄ¾Ç

Ź¿ùÇÑ ¿­´ëº´ Áø´Ü ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. À§ÀÇ ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­ ¹× ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í °ø±Þ¾÷ü´Â °æÀïÀÌ Ä¡¿­ ÇØÁü¿¡ µû¶ó ÀÚ½ÅÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÃæºÐÇÑ Á¤º¸¸¦ ±â¹ÝÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÐÇÒÇϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·«ºÐ¼®°ú Ãßõ : ¼Ò¿Ü¿­´ëÁúȯ Áø´Ü½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸®±â

¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¼Ò¿Ü¿­´ëÁúȯ¿¡ ÀÓÇÏ´Â ÇÁ·Î±×·¥ Áõ°¡
      • ¿­´ë¡¤¾Æ¿­´ë ±¹°¡¿¡¼­ ¹«½ÃµÇ±â ½Ê»óÀÎ ¿­´ëº´ÀÇ ¸¸¿¬·ü »ó½Â
      • Áúº´ÀÇ Á¶±â ¹ß°ß¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
    • ¾ïÁ¦¿äÀÎ
      • °³¹ßµµ»ó±¹¿¡¼­ ¼Ò¿Ü¿­´ëÁúȯÀÇ Ä¡·áÀνÄÀÇ ºÎÁ·
    • ±âȸ
      • ¼±ÁøÀûÀÎ ¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ÀåÄ¡ÀÇ °³¹ßÀÌ ÁøÇàµÈ´Ù
      • Çõ½ÅÀûÀÎ ¼Ò¿Ü¿­´ëÁúȯÀÇ Áø´Ü¹ýÀ» °³¹ßÇϱâ À§ÇÑ ¿¬±¸°³¹ßÀÇ °íÁ¶
    • °úÁ¦
      • Áø´ÜÀ» À§ÇÑ Ç¥ÁØÈ­ ÅøÀÇ ºÎÁ·
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå ¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ½ÃÀå :¼­ºñ½ºº°

  • ÁýÁß ¼­ºñ½º
  • POC ¼­ºñ½º

Á¦7Àå ¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ½ÃÀå :Áúȯº°

  • ¾ÆÇÁ¸®Ä« ¼ö¸éº´
  • ºÎ·ê¸® ±Ë¾ç
  • »þ°¡½ºº´
  • Ä¡Äﱸ´Ï¾Æ º´
  • µ­±â¿­
  • ¸Þµð³ªÃæÁõ
  • Æ÷ÃæÁõ
  • ½ÄÁßµ¶±Õ
  • ¸®½´¸¶´Ï¾îÁõ
  • ³ªº´
  • ¸²ÇÁ°è Çʶ󸮾ÆÁõ
  • »ç»óÃæÁõ
  • ±¤°ßº´
  • ¿È
  • ÁÖÇ÷ÈíÃæº´
  • ¹ì¿¡ ¹°·Á µ¶ °¨¿°
  • Åä¾ç ÀüÆÄ ±â»ýÃæ °¨¿°Áõ
  • Á¶ÃæÁõ/³¶ÃæÁõ
  • ¸ÅÁ¾

Á¦8Àå ¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ½ÃÀå : Áø´Ü ¹æ¹ýº°

  • Á¾·¡ÀÇ ¹æ¹ý
  • ºÐÀÚ/Çö´ëÀû ¹æ¹ý

Á¦9Àå ¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ½ÃÀå : ÃÖÁ¾ ¿ëµµº°

  • ÀÓ»ó ½ÇÇè½Ç
  • ÀçÅà ÇコÄɾî
  • º´¿ø/Ŭ¸®´Ð

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¼Ò¿Ü¿­´ëÁúȯ Áø´Ü ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • Coris BioConcept SPRL
  • DiaSys Diagnostic Systems GmbH
  • F. Hoffmann-La Roche Ltd
  • Genome Diagnostics Pvt. Ltd.
  • InBios International, Inc.
  • Omega Diagnostics Group PLC
  • Ortho Clinical Diagnostics
  • Oscar Medicare Pvt. Ltd.
  • Premier Medical Corporation Ltd.
  • Siemens AG
  • Thermo Fisher Scientific Inc.
  • ZeptoMetrix LLC
JHS 24.12.20

The Neglected Tropical Diseases Diagnosis Market was valued at USD 6.69 billion in 2023, expected to reach USD 7.04 billion in 2024, and is projected to grow at a CAGR of 5.80%, to USD 9.93 billion by 2030.

Neglected Tropical Diseases (NTDs) include a diverse array of infections affecting over a billion people primarily in tropical and subtropical regions. Defined by their impact on impoverished populations, they significantly hinder economic development and societal progression. The necessity of accurate NTD diagnosis underlies these diseases' ability to cause chronic health issues, debilitating infections, and societal stigma. Applications span from basic diagnostic tools to advanced molecular methodologies, crucial for disease surveillance, effective treatment planning, and transmission reduction. End-use sectors include hospitals, diagnostic laboratories, and research institutions, which utilize these diagnoses to manage outbreaks, guide healthcare policy, and conduct epidemiological studies. Market growth for NTD diagnoses is driven by increased global health funding, heightened awareness, and technological advancements in diagnostic techniques. A growing number of public-private partnerships and global health initiatives emphasize early detection, accurate diagnostics, and cost-effective solutions, presenting opportunities for market expansion. Key growth factors include increased governmental and non-governmental investments, innovation in diagnostic technologies like molecular and point-of-care testing, and expanding access to healthcare in regions burdened by NTDs. However, market challenges include inadequate healthcare infrastructure in endemic regions, limited awareness, regulatory barriers, and the high cost of advanced diagnostic tools. Opportunities exist in developing low-cost, rapid diagnostic tests for NTDs, particularly those deployable in low-resource settings. Innovation can focus on portable and integrated diagnostic platforms that provide quick and accurate results, potentially augmented by digital health technologies for data dissemination and management. To capitalize on these opportunities, companies should focus on strategic collaborations with governments and NGOs, invest in R&D for novel diagnostics, and work towards scalable production techniques. Due diligence must be executed in navigating stringent regulatory environments and addressing healthcare delivery barriers to sustainably grow within this market.

KEY MARKET STATISTICS
Base Year [2023] USD 6.69 billion
Estimated Year [2024] USD 7.04 billion
Forecast Year [2030] USD 9.93 billion
CAGR (%) 5.80%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neglected Tropical Diseases Diagnosis Market

The Neglected Tropical Diseases Diagnosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in number of programs to tackle neglected tropical diseases
    • Rising prevalence of neglected tropical diseases in tropical and subtropical countries
    • Growing demand for early disease identification
  • Market Restraints
    • Lack of neglected tropical diseases treatment awareness in underdeveloped countries
  • Market Opportunities
    • Growing development of advanced neglected tropical disease diagnosis devices
    • Rising R&D to develop innovative neglected tropical disease diagnosis
  • Market Challenges
    • Lack of standardization tools for diagnosis

Porter's Five Forces: A Strategic Tool for Navigating the Neglected Tropical Diseases Diagnosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neglected Tropical Diseases Diagnosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neglected Tropical Diseases Diagnosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neglected Tropical Diseases Diagnosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neglected Tropical Diseases Diagnosis Market

A detailed market share analysis in the Neglected Tropical Diseases Diagnosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neglected Tropical Diseases Diagnosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neglected Tropical Diseases Diagnosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neglected Tropical Diseases Diagnosis Market

A strategic analysis of the Neglected Tropical Diseases Diagnosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neglected Tropical Diseases Diagnosis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Bio-Rad Laboratories, Inc., Coris BioConcept SPRL, DiaSys Diagnostic Systems GmbH, F. Hoffmann-La Roche Ltd, Genome Diagnostics Pvt. Ltd., InBios International, Inc., Omega Diagnostics Group PLC, Ortho Clinical Diagnostics, Oscar Medicare Pvt. Ltd., Premier Medical Corporation Ltd., Siemens AG, Thermo Fisher Scientific Inc., and ZeptoMetrix LLC.

Market Segmentation & Coverage

This research report categorizes the Neglected Tropical Diseases Diagnosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Service, market is studied across Centralized Service and POC Service.
  • Based on Disease, market is studied across African Trypanosomiasis, Buruli Ulcer, Chagas Disease, Chikungunya, Dengue, Dracunculiasis, Echinococcosis, Foodborne Trematodiases, Leishmaniasis, Leprosy, Lymphatic Filariasis, Onchocerciasis, Rabies, Scabies, Schistosomiasis, Snakebite Envenoming, Soil-transmitted Helminth Infections, Taeniasis/Cysticercosis, and Yaws.
  • Based on Diagnostic Method, market is studied across Conventional Method and Molecular/Modern Method.
  • Based on End-Use, market is studied across Clinical Labs, Home Healthcare, and Hospitals /Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in number of programs to tackle neglected tropical diseases
      • 5.1.1.2. Rising prevalence of neglected tropical diseases in tropical and subtropical countries
      • 5.1.1.3. Growing demand for early disease identification
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of neglected tropical diseases treatment awareness in underdeveloped countries
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing development of advanced neglected tropical disease diagnosis devices
      • 5.1.3.2. Rising R&D to develop innovative neglected tropical disease diagnosis
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of standardization tools for diagnosis
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Neglected Tropical Diseases Diagnosis Market, by Service

  • 6.1. Introduction
  • 6.2. Centralized Service
  • 6.3. POC Service

7. Neglected Tropical Diseases Diagnosis Market, by Disease

  • 7.1. Introduction
  • 7.2. African Trypanosomiasis
  • 7.3. Buruli Ulcer
  • 7.4. Chagas Disease
  • 7.5. Chikungunya
  • 7.6. Dengue
  • 7.7. Dracunculiasis
  • 7.8. Echinococcosis
  • 7.9. Foodborne Trematodiases
  • 7.10. Leishmaniasis
  • 7.11. Leprosy
  • 7.12. Lymphatic Filariasis
  • 7.13. Onchocerciasis
  • 7.14. Rabies
  • 7.15. Scabies
  • 7.16. Schistosomiasis
  • 7.17. Snakebite Envenoming
  • 7.18. Soil-transmitted Helminth Infections
  • 7.19. Taeniasis/Cysticercosis
  • 7.20. Yaws

8. Neglected Tropical Diseases Diagnosis Market, by Diagnostic Method

  • 8.1. Introduction
  • 8.2. Conventional Method
  • 8.3. Molecular/Modern Method

9. Neglected Tropical Diseases Diagnosis Market, by End-Use

  • 9.1. Introduction
  • 9.2. Clinical Labs
  • 9.3. Home Healthcare
  • 9.4. Hospitals /Clinics

10. Americas Neglected Tropical Diseases Diagnosis Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Neglected Tropical Diseases Diagnosis Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Neglected Tropical Diseases Diagnosis Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Bio-Rad Laboratories, Inc.
  • 3. Coris BioConcept SPRL
  • 4. DiaSys Diagnostic Systems GmbH
  • 5. F. Hoffmann-La Roche Ltd
  • 6. Genome Diagnostics Pvt. Ltd.
  • 7. InBios International, Inc.
  • 8. Omega Diagnostics Group PLC
  • 9. Ortho Clinical Diagnostics
  • 10. Oscar Medicare Pvt. Ltd.
  • 11. Premier Medical Corporation Ltd.
  • 12. Siemens AG
  • 13. Thermo Fisher Scientific Inc.
  • 14. ZeptoMetrix LLC
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦